VistaGen Therapeutics (VTGN) Received its Third Buy in a Row


After Maxim Group and Oppenheimer gave VistaGen Therapeutics (NASDAQ: VTGN) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on VistaGen Therapeutics today and set a price target of $22. The company’s shares opened today at $1.70.

Amusa noted:

“We believe the company is well positioned to achieve accelerated development of AV-101 in multiple indications with high unmet needs given the various benefits of FTD, which include a rolling review.”

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 23.5% and a 51.6% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

VistaGen Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.65 and a one-year low of $0.69. Currently, VistaGen Therapeutics has an average volume of 179.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts